Sharon Wilks - Concepedia

Author

Sharon Wilks

Also Known As

David Tamura, S Wilks, S. Wilks, S.T. Wilks, Samuel Wilks, Sharon T Wilks, Sharon T. Wilks, Sharon Wilks, Sharon. Wilks, Wilks S

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Texas Oncology Sarah Cannon Tennessee Oncology Rocky Mountain Cancer Centers Baylor University Medical Center

About

Sharon Wilks is an author at Texas Oncology specializing in medicine, cancer therapeutics, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	17	1.7K
2	Health Sciences	5	5	1.3K
3	Cell Biology	4	4	258
4	Immunology	2	2	106
5	Gastroenterology	1	1	11

Sharon Wilks

Publications

Citations

H-Index

Page 1

	Year	Citations
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA M.C. Liu, Geoffrey R. Oxnard, Eric A. Klein, Annals of Oncology	2020	1.4K
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Fabrice André, Ruth O’Regan, Mustafa Özgüroğlu, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyPlacebo-controlled Phase 3Clinical Trials	2014	489
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3 Fabrice André, Sara A. Hurvitz, Angelica Fasolo, Journal of Clinical Oncology	2016	165
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer Hui Yu, Cory Batenchuk, A. Badzio, Journal of Thoracic Oncology OncologyPd-l1 ExpressionMedicinePathologyCancer Genomics	2016	134
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani, Clinical Cancer Research	2021	134
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial Denise A. Yardley, Rob Coleman, Pierfranco Conté, Annals of Oncology	2018	130
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial Antoinette R. Tan, Gail S. Wright, Anu Thummala, The Lancet Oncology Chemotherapy Versus ChemotherapyBreast OncologyMedicineBreast CancerPharmacotherapy	2019	111
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer Aditya Bardia, Virginia Kaklamani, Sharon Wilks, Journal of Clinical Oncology	2021	106
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial Ignace Vergote, Giovanni Scambia, David M. O’Malley, The Lancet Oncology Advanced Ovarian CancerMedicinePharmacologyGynecologyFirst-line Treatment	2019	85

Page 1